Your shopping cart is currently empty

Z57346765 is a specific PGK1(Phosphoglycerate kinase 1) inhibitor that inhibits PGK1-dependent cell proliferation by decreasing the metabolic enzyme activity of PGK1 during glycolysis. In the clinical phase, Z57346765 had a dose-dependent inhibitory effect on locally advanced renal clear cell carcinoma (KIRC) by inducing changes in the expression of genes related to cell metabolism, DNA replication, and the cell cycle.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $45 | - | In Stock | |
| 5 mg | $107 | - | In Stock | |
| 10 mg | $162 | - | In Stock | |
| 25 mg | $323 | - | In Stock | |
| 50 mg | $488 | - | In Stock | |
| 100 mg | $733 | - | In Stock | |
| 200 mg | $987 | - | In Stock |
| Description | Z57346765 is a specific PGK1(Phosphoglycerate kinase 1) inhibitor that inhibits PGK1-dependent cell proliferation by decreasing the metabolic enzyme activity of PGK1 during glycolysis. In the clinical phase, Z57346765 had a dose-dependent inhibitory effect on locally advanced renal clear cell carcinoma (KIRC) by inducing changes in the expression of genes related to cell metabolism, DNA replication, and the cell cycle. |
| Synonyms | Z 57346765 |
| Molecular Weight | 294.35 |
| Formula | C17H18N4O |
| Cas No. | 1016340-64-9 |
| Smiles | OCCNC=1N=C(N=C2C=CC=CC21)NC3=CC=C(C=C3)C |
| Storage | store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (271.79 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (11.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.